We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reduced‐dose bacillus Calmette‐Guérin (BCG) in an era of BCG shortage: real‐world experience from a tertiary cancer centre.
- Authors
Lobo, Niyati; Bree, Kelly K.; Hensley, Patrick J.; Nogueras‐Gonzalez, Graciela M.; Abraham, Prasanth; Navai, Neema; Dinney, Colin P.; Kamat, Ashish M.
- Abstract
Objective: To evaluate the impact of one‐third‐dose (1/3D) bacillus Calmette‐Guérin (BCG) on oncological outcomes in a large cohort of patients with non‐muscle‐invasive bladder cancer (NMIBC) treated with adequate BCG (as defined by the US Food & Drug Administration (FDA)) in a real‐world setting. Patients and Methods: We performed an institutional review board‐approved review of patients with NMIBC treated with adequate BCG at our institution between 2000 and 2020. Patients were stratified according to whether they had received 1/3D BCG or full‐dose (FD) BCG. Time to recurrence, time to progression and cancer‐specific survival were estimated using Kaplan–Meier methods. Results: Of 563 patients with NMIBC treated with adequate BCG, 150 (26.6%) received 1/3D and 413 (73.4%) received FD. The use of 1/3D BCG did not adversely affect time to recurrence (P = 0.449) or time to progression (P = 0.716), and this remained consistent when patients were stratified by individual 2021 European Association of Urology (EAU) prognostic factor risk groups. Cancer‐specific survival was similar in patients receiving 1/3D and those receiving FD BCG (P = 0.320). Conclusion: The use of 1/3D BCG was not associated with adverse oncological outcomes in a large cohort of patients receiving adequate BCG for intermediate‐ and high‐risk NMIBC. Based on this real‐world experience, risk‐stratified split‐vial dosing may represent a valuable approach for other institutions facing BCG shortages whilst also providing reassurance to patients who may be concerned about suboptimal outcomes.
- Subjects
CANCER invasiveness; SCARCITY; BLADDER cancer; PROGNOSIS
- Publication
BJU International, 2022, Vol 130, Issue 3, p323
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1111/bju.15661